ALLMedicine™ Growth Hormone Center

Dec 4th, 2021 - Suppressor of cytokine signaling (SOCS)2 protein is a key negative regulator of the growth hormone (GH) and Janus kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) signaling cascade. The central SOCS2-Src homology 2 (SH2) doma...

Dec 3rd, 2021 - Background and Objective: Acyl-ghrelin is a 28-amino acid peptide that stimulates appetite and food intake. It is an endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a). Preclinical studies suggest that acyl-ghrelin increases ...

Dec 3rd, 2021 - The management of uterine leiomyosarcomas (uLMS) remains challenging. The rate of recurrence and metastasis is high, with 5-yr survival reaching only 40% to 50% in patients with tumor confined to the uterus (FIGO stage I or II). Prolactin receptor...

Dec 3rd, 2021 - Hexarelin, a synthetic growth hormone-releasing peptide, is shown to be protective in cardiovascular diseases such as myocardial infraction and atherosclerosis. However, the functional role of hexarelin in abdominal aortic aneurysm (AAA) remains u...

Dec 2nd, 2021 - Human growth hormone (hGH) provocation test is an essential tool to assess growth hormone deficiency (GHD) in children and young adults. It is important to have a robust method to determine the hGH peak of stimulation. This work aimed to compare t...

Jun 15th, 2019 - Achieving normal growth is one of the most challenging problems in the management of children with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables children with CKD...

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Dec 23rd, 2014 - Optimisation of the environment favourable for satisfactory ovarian response to stimulation and successful embryo implantation remains at the core of assisted conception programmes. The evidence base for the routine use of different adjuvants, alo...

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

Dec 3rd, 2021 - Background and Objective: Acyl-ghrelin is a 28-amino acid peptide that stimulates appetite and food intake. It is an endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a). Preclinical studies suggest that acyl-ghrelin increases ...

Nov 29th, 2021 - This is a single center study. All participants will be recruited from the USA. The study intends to recruit pre-pubertal children for inclusion in the 1 year growth hormone treatment trial. The study also plans to collect the following detailed p...

Nov 26th, 2021 - Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of...

Nov 18th, 2021 - Adolescents with anorexia nervosa (AN) are at high risk for low bone mineral density at a time when healthy adolescents are rapidly accruing bone, with implications for peak bone mass and fracture risk in later life. They are also deficient in ins...

Nov 10th, 2021 - Compared with the placebo, rhGH treatment significantly decreased the total scores and subscale scores of GDS (P <0.05), while the total scores and subscale scores of SC-ABC significantly decreased (P < 0.05) following three-months rhGH treatment....

Nov 16th, 2021 - The European Medicines Agency (EMA) has given the 'green light' to lonapegsomatropin (TransCon hGH, Ascendis Pharma), a long-acting, once-weekly formulation of human growth hormone, for growth failure in children and adolescents, aged 3 to 18 year...

Nov 3rd, 2021 - People who carry loss-of-function mutations in MC3R have later onset of puberty, researchers found. Over 800 females carrying a MC3R mutation had a 4.7-month delay in age at menarche compared with non-carriers, reported Stephen O'Rahilly, MD, of t...

Sep 2nd, 2021 - The US Food and Drug Administration (FDA) has approved lonapegsomatropin (Skytrofa, Ascendis Pharma), the first weekly subcutaneous injectable growth hormone for children with growth hormone deficiency (GHD). The approval was based on the findings...

Aug 31st, 2021 - Key clinical point: Adding trastuzumab to chemotherapy in patients with early-stage, epidermal growth hormone receptor 2 (HER2)-positive breast cancer lowers the rate of recurrence and mortality from breast cancer. Major finding: Trastuzumab plus.

Apr 2nd, 2021 - Transcript: Adam Brufsky, MD, PhD: Virginia, what are your first- and second-line standards of care right now for metastatic HER2 [human epidermal growth hormone receptor 2]–breast cancer? Virginia Kaklamani, MD:Assuming somebody has not ju...